Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Influenza Vaccine stories

Sep 1, 2026

GSK advances mRNA flu vaccine to late-stage trial after strong mid-stage results

GSK will advance its mRNA-based seasonal influenza vaccine to late-stage trials after mid-stage data showed it generated stronger immune responses than currently approved flu vaccines.

Sep 1, 2026·2 sources
00

Top claims

  • ▪GSK intends to begin the late-stage trial for its mRNA-based seasonal influenza vaccine candidate in September 2026
  • ▪GSK stated that targeting both haemagglutinin and neuraminidase surface proteins could improve protection against seasonal influenza and reduce transmission
  • ▪In August 2026, Moderna won U.S. approval for its seasonal flu vaccine mFlusiva, which is the first mRNA-based vaccine approved for seasonal flu

Topics

Drug Policy, Pricing & ApprovalClinical trialsVaccines and Immunization PolicyDrug Approval and Clinical TrialsVaccine development and innovation

Related entities

Immunology